FMED Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.93%, SMA50 -2.22%, SMA200 3.37%). The stock’s 14-day RSI is 48.68 (neutral), while the ATR of 0.41 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -9.54% below its high and over 27.12% above its low. Average 10-day trading volume of 4.69 thousand shares is below the 3-month average of 6.70 thousand, indicating normal recent market interest.

Our AI price prediction model suggests that Fidelity Disruptive Medicine ETF stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

currently trading near 52-week highs band.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) closed at $31.00 USD, gaining $0.16 (0.51%) from the previous close of $30.84. The stock is currently mid-range between its 52-week high and low $23.48 and $32.89. With a market capitalization of about $70.88 million, Fidelity Disruptive Medicine ETF is classified as a micro-cap and shows lower-than-market volatility (beta ~0.78). Key stats such as the average daily volume over the past year has been around 6.72 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Fidelity Disruptive Medicine ETF operates in the Financial Services sector and the Asset Management industry. This exchange-traded fund allocates capital to pioneering enterprises reshaping medical detection, treatments, and care delivery, encompassing areas from genetic manipulation to automated surgical procedures and online health ecosystems.